Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-3409207
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Hemostemix (CVE:HEM) Frequently Asked Questions
What is Hemostemix's stock symbol?
Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."
Has Hemostemix been receiving favorable news coverage?
Media coverage about HEM stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hemostemix earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Hemostemix.
Who are some of Hemostemix's key competitors?
Some companies that are related to Hemostemix include Tissue Regenix Group (TRX), Redx Pharma (REDX), AorTech International (AOR), Ibio (IBIO), Living Cell Technologies (LCT), iCo Therapeutics (ICO), Nuvo Pharmaceuticals (NRI), OKYO Pharma (OKYO), Naturally Splendid Enterprises (NSP), Medibio (MEB), Ovoca Bio (OVB), Synthetic Biologics (SYN), Synthetic Biologics (SYN), Hemogenyx Pharmaceuticals (HEMO) and Pascal Biosciences (PAS).
What other stocks do shareholders of Hemostemix own?
Who are Hemostemix's key executives?
Hemostemix's management team includes the folowing people:
- Mr. Kyle Makofka, Chief Exec. Officer
- Ms. Kristin Gulka CPA, CA, Chief Financial Officer
- Ms. Eilat Bain, Director of Operations
- Dr. Alan J. Jacobs, Chief Medical Consultant
How do I buy shares of Hemostemix?
Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Hemostemix's stock price today?
One share of HEM stock can currently be purchased for approximately C$0.01.
How big of a company is Hemostemix?
What is Hemostemix's official website?
How can I contact Hemostemix?
Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.
MarketBeat Community Rating for Hemostemix (CVE HEM)
MarketBeat's community ratings are surveys of what our community members think about Hemostemix and other stocks. Vote "Outperform" if you believe HEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
